TELA Bio gains FDA clearance for resorbable surgical mesh

TELA Bio's new surgical mesh receives FDA clearance

TELA Bio Inc., based in Malvern, Pennsylvania, has secured clearance from the U.S. Food and Drug Administration (FDA) for its Liora Monofilament Scaffold, a fully resorbable surgical mesh. This development, announced on October 5, marks a significant expansion of the company's soft-tissue reconstruction offerings.

What the FDA clearance entails

The FDA granted a 510(k) clearance for the Liora Monofilament Scaffold, a synthetic implant designed to reinforce soft tissue during surgeries. This clearance allows TELA Bio to market the device, confirming it is substantially equivalent to an existing legally marketed device. The 510(k) process is distinct from the FDA's more rigorous premarket approval pathway.

Expansion of TELA Bio's product line

The Liora Scaffold is TELA Bio's first fully resorbable synthetic product developed and manufactured in-house at its Malvern facility. The company operates an ISO 8-certified cleanroom for its controlled-environment manufacturing processes. This new product line enhances TELA Bio's capabilities in the soft-tissue reconstruction market, where surgical meshes are crucial for tissue repair.

Why it matters

The introduction of the Liora Monofilament Scaffold represents a strategic advancement for TELA Bio, highlighting its commitment to internal product development and manufacturing. "FDA 510(k) clearance is a significant milestone for TELA Bio," said CEO Heather Getz. "The addition of Liora to our portfolio expands the options available to surgeons and patients for their soft tissue reconstruction needs."

Future developments

TELA Bio plans to provide further details about the Liora Monofilament Scaffold during its third-quarter earnings conference call, anticipated in early November. This announcement underscores the company's ongoing investment in innovative engineering and product development.

TELA Bio's latest FDA clearance not only broadens its product offerings but also reinforces its position in the competitive medical technology landscape.